Cellectis (CLLS) Return on Capital Employed (2015 - 2026)
Cellectis (CLLS) posted quarterly Return on Capital Employed of 25.55% for Q1 2026, down 54.0% year-over-year from 55.55% in Q1 2025, and down 45.33% quarter-over-quarter from 17.58% in Q4 2025.
Cellectis (CLLS) Return on Capital Employed (2015 - 2026) Analysis & Trends
Cellectis' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 25.55% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 54.0% year-over-year to 25.55%; the TTM figure through Mar 2026 stood at 25.55% (down 54.0% YoY), while the FY2025 annual figure was 28.58%, up 234.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 25.55%, down from 17.58% in the prior quarter.
- The five-year high for Return on Capital Employed was 13.21% in Q3 2025, with the low at 83.28% in Q4 2023.
- The 5-year median for Return on Capital Employed is 39.95% (2024), against an average of 37.18%.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 4299 bps in 2023, then jumped 5662 bps in 2024.
- Cellectis' Return on Capital Employed stood at 40.29% in 2022, then plunged by 107 bps to 83.28% in 2023, then surged by 68 bps to 26.65% in 2024, then jumped by 34 bps to 17.58% in 2025, then tumbled by 45 bps to 25.55% in 2026.
- Business Quant data shows CLLS's Return on Capital Employed at 25.55% in Q1 2026, 17.58% in Q4 2025, and 13.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -25.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.55% |
| Dec 31, 2025 | -17.58% |
| Sep 30, 2025 | -13.21% |
| Jun 30, 2025 | -23.60% |
| Mar 31, 2025 | -25.01% |
| Dec 31, 2024 | -26.65% |
| Sep 30, 2024 | -33.26% |
| Jun 30, 2024 | -39.95% |
| Mar 31, 2024 | -50.97% |
| Dec 31, 2023 | -83.28% |
| Sep 30, 2023 | -42.00% |
| Jun 30, 2023 | -40.54% |
| Mar 31, 2023 | -39.29% |
| Dec 31, 2022 | -40.29% |
| Sep 30, 2022 | -43.87% |
| Jun 30, 2022 | -44.29% |
| Mar 31, 2022 | -42.79% |
| Dec 31, 2021 | -35.71% |
| Sep 30, 2021 | -15.71% |
| Jun 30, 2021 | -11.93% |